구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD-1 Monoclonal Antibody REGN2810 (Anti-PD-1 Monoclonal Antibody REGN2810) Sidney Kimmel Comprehensive Cancer…·PD-1 1 trials |
|---|---|
Overview Program | Anti-PD-1 Monoclonal Antibody REGN2810 |
Overview Company | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Stage III Prostate Cancer; Stage IIIA Prostate Cancer |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.. Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are not candidates for surgery or radiation. In addition to PD-1 inhibitors, pembrolizumab and cemiplimab, cosibelimab, a PD-L1… |
Clinical Safety signal | Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.. Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are not candidates for surgery or radiation. In addition to PD-1 inhibitors, pembrolizumab and cemiplimab, cosibelimab, a PD-L1… |
Clinical Selected reported efficacy | ORR 52% |
Clinical Reported ORR | 52% |
Clinical Result source | ClinicalTrials.gov NCT03257267 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03257267 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD-1 Monoclonal Antibody REGN2810 (Anti-PD-1 Monoclonal Antibody REGN2810) Sidney Kimmel Comprehensive Cancer…·PD-1 1 trials |
|---|---|
Overview Program | Anti-PD-1 Monoclonal Antibody REGN2810 |
Overview Company | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Stage III Prostate Cancer; Stage IIIA Prostate Cancer |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.. Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are not candidates for surgery or radiation. In addition to PD-1 inhibitors, pembrolizumab and cemiplimab, cosibelimab, a PD-L1… |
Clinical Safety signal | Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.. Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are not candidates for surgery or radiation. In addition to PD-1 inhibitors, pembrolizumab and cemiplimab, cosibelimab, a PD-L1… |
Clinical Selected reported efficacy | ORR 52% |
Clinical Reported ORR | 52% |
Clinical Result source | ClinicalTrials.gov NCT03257267 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03257267 |
추천 비교
추천 비교